BioCentury | Apr 2, 2012
Finance

Doubling down

Biotech investors lifted valuations across the board last quarter and made a handful of big bets that were driven by potential acquisitions, lawsuit settlements, strong earnings and positive clinical and regulatory news. At least one...
BC Week In Review | Feb 27, 2012
Clinical News

Cartistem regulatory update

Medipost said the Korea Food and Drug Administration approved Cartistem to treat osteoarthritis. Cartistem consists of allogeneic mesenchymal stem cells from umbilical cord blood. The product is marketed in Korea by partner Dong-A Pharmaceutical Co....
BC Extra | Feb 23, 2012
Company News

Korea approves Medipost's mesenchymal stem cell therapy

Medipost (KOSDAQ:078160) said the Korean FDA approved Cartistem to treat osteoarthritis. Cartistem consists of allogeneic mesenchymal stem cells from umbilical cord blood. The product is marketed in Korea by partner Dong-A Pharmaceutical Co. Ltd. (KSE:000640)....
Items per page:
1 - 3 of 3